Session » (2326–2351) SLE – Treatment Poster III
-
Abstract Number: 2326
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
-
Abstract Number: 2327
Hydroxychloroquine Improves Low Complement Levels
-
Abstract Number: 2328
Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
-
Abstract Number: 2329
AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo
-
Abstract Number: 2330
Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis
-
Abstract Number: 2331
Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus
-
Abstract Number: 2332
Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data
-
Abstract Number: 2333
Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
-
Abstract Number: 2334
Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
-
Abstract Number: 2335
Defining a Basket Population for ANA+ Arthritis Trials
-
Abstract Number: 2336
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
-
Abstract Number: 2337
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
-
Abstract Number: 2338
Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
-
Abstract Number: 2339
Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies
-
Abstract Number: 2340
Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
-
Abstract Number: 2341
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2342
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
-
Abstract Number: 2343
Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
-
Abstract Number: 2344
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
-
Abstract Number: 2345
Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis
-
Abstract Number: 2346
SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
-
Abstract Number: 2347
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
-
Abstract Number: 2348
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years